Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Dr Reddys, Dept of...

    Dr Reddys, Dept of Science and Technology, Hyderabad University to develop anti-psoriatic drugs

    Written by Ruby Khatun Khatun Published On 2017-05-25T13:34:45+05:30  |  Updated On 25 May 2017 1:34 PM IST
    Dr Reddys, Dept of Science and Technology, Hyderabad University to develop anti-psoriatic drugs

    Hyderabad: The Department of Science and Technology (DST), Dr Reddys Laboratories (DRL) and University of Hyderabad (UoH) have joined hands to initiate a project on discovery and development of anti-psoriatic drugs.


    The three entities today signed an agreement in this regard.



    "An agreement has been signed between DST, DRL, UoH and Dr Reddys Institute of Life Sciences (DRILS) to initiate a project for discovery and development of drugs against psoriasis," a release from UoH said here.

    The venture, valued at Rs 1.90 crore, has been sponsored by DST and DRL, it said.


    Psoriasis is a autoimmune disease which is characterised by patches of abnormal skin.


    The market size for drugs for psoriasis and other skin disorders is currently about USD 6-7 billion and expected to reach about USD 13 billion in a span of 10 years, it said.


    Most approved therapies for psoriasis are symptomatic. The specific disease modifying therapies include monoclonal antibodies, which are expensive and have safety and tolerability issues, the release said.


    The project proposes development of selective inhibitors of 12R-LOX (a type of enzyme) by employing conventional as well as the molecular modelling and drug design approaches, the release said.

    department of science and technologyDr Reddy'sDr Reddy's LaboratoriesDr Reddys Institute of Life SciencesUniversity of Hyderabad
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok